Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →